Difference between revisions of "Amifostine (Ethyol)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 20: | Line 20: | ||
[[Category:Chemotherapy protective agents]] | [[Category:Chemotherapy protective agents]] | ||
| − | [[Category: | + | [[Category:FDA approved in 1995]] |
Revision as of 19:17, 30 July 2018
General information
Class/mechanism: Prodrug of a free thiol metabolite, converted to the active form by alkaline phosphatase, that reduces the cumulative renal toxicity of cisplatin and oral toxicity of radiation by scavaging reactive metabolites and reactive oxygen species. Amifostine is thought to preferentially protect normal tissues because they have higher alkaline phosphatase activity, higher pH, and better vascularity.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Amifostine (Ethyol) patient drug information (Chemocare)[3]
- Amifostine (Ethyol) patient drug information (UpToDate)[4]
Also known as
- Brand names: Cytofos, Ethyol